Table 4

Multivariate analysis
Overall survival
Model 1 Model 2 Model 3
HR (95%CI) p= HR (95%CI) p= HR (95%CI) p=
PSA,ng/ml
≤10ng/ml 1.0 1.0 1.0
>10ng/ml 0.54 (0.15-2.03) 0.4 0.48 (0.12-1.86) 0.3 0.48 (0.12-1.87) 0.3
Extra-prostatic extension
Yes 1.0 1.0 (0.76-17.35) 1.0
No 3.43 (0.73-16.12) 0.1 3.63 0.1 3.48 (0.73-16.54) 0.1
Pelvic nodes involved
N0 1.0 1.0 1.0
N+ 1.71 (0.50-5.79) 0.4 1.44 (0.43-4.83) 0.5 1.40 (0.42-4.72) 0.6
Surgical margins involved
No 1.0 1.0 1.0
Yes 1.37 (0.45-4.21) 0.6 1.38 (0.47-4.01) 0.6 1.33 (0.45-3.92) 0.6
Seminal vesicles involved
No 1.0 1.0 1.0
Yes 1.39 (0.49-3.94) 0.5 1.08 (0.37-3.10) 0.9 1.11 (0.38-3.25) 0.8
Gleason score
<7 1.0
≥7 2.13 (0.55-8.19) 0.3
Gleason score
≤7 1.0
>7 2.80 (0.93-8.47) 0.07
Gleason score
<7 1.0 0.1
=7 1.43 (0.32-6.40) 0.6
>7 3.52 (0.79-15.61) 0.1
Epithelial IRS
>2 1.0 1.0 1.0
≤2 3.22 (0.56-18.48) 0.2 3.09 (0.51-18.63) 0.2 3.19 (0.52-19.47) 0.2
Stroma IRS
<12 1.0 1.0 1.0
=12 5.85 (1.82-18.77) 0.003 5.76 (1.84-18.07) 0.003 5.99 (1.87-19.22) 0.003

Abbreviations:HR,Hazard Ratio;CI Confidence Interval;PSA,Prostate-specific antigen;IRS Immuno-reactive score.

Nuzzo et al.

Nuzzo et al. BMC Cancer 2012 12:625   doi:10.1186/1471-2407-12-625

Open Data